Sermorelin Research Compound
Research Use Only
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, food, cosmetic, household, or agricultural applications. Not for human consumption.
Overview
Sermorelin (GHRH 1-29) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-44). This truncated form retains full biological activity, as the C-terminal portion of native GHRH is not required for receptor binding and activation. Sermorelin was previously FDA-approved (Geref) for pediatric GH deficiency, providing a well-documented clinical history and safety profile.
Molecular Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C149H246N44O42S |
| Molecular Weight | 3357.88 g/mol |
| CAS Number | 86168-78-7 |
| Amino Acids | 29 |
| Sequence | GHRH (1-29) with C-terminal amide |
| Purity | ≥99% (HPLC) |
| Storage | -20°C, protected from light |
Mechanism of Action
Sermorelin stimulates GH release via GHRH receptor activation:
Pituitary Stimulation
- Binding to GHRH receptors on somatotrophs
- cAMP pathway activation
- GH gene transcription enhancement
- GH synthesis and secretion
Physiological Regulation
- Maintains natural pulsatile GH release
- Preserves negative feedback mechanisms
- IGF-1 axis stimulation
- Somatostatin sensitivity maintained
Trophic Effects
- Pituitary somatotroph maintenance
- Prevention of GH-producing cell atrophy
- Endogenous capacity preservation
Research Applications
Growth Hormone Studies
- GH deficiency models
- Age-related GH decline research
- Pituitary function assessment
- Pediatric growth studies
Comparative Secretagogue Research
- Efficacy vs. modified analogs (CJC-1295)
- Safety profile comparisons
- Long-term protocol studies
- Combination therapy research
Clinical Translation Research
- Dosing optimization
- Administration route studies
- Biomarker response
- Safety monitoring protocols
Available Formats
| Size | Format | Catalog Code |
|---|---|---|
| 2mg | Lyophilized | SER-2 |
| 5mg | Lyophilized | SER-5 |
| 10mg | Lyophilized | SER-10 |
Handling & Storage
- Store lyophilized peptide at -20°C
- Protect from light and moisture
- Reconstitute with bacteriostatic water
- Reconstituted solution stable at 2-8°C for up to 4 weeks
- Avoid repeated freeze-thaw cycles
Quality Specifications
- Purity: ≥99% by HPLC
- Appearance: White lyophilized powder
- Solubility: Soluble in water
- Endotoxin: Less than 1 EU/mg
- Certificate of Analysis provided
Clinical History
| Phase | Notes |
|---|---|
| FDA Approval | 1997 (Geref) for pediatric GH deficiency |
| Withdrawal | 2008 (commercial reasons, not safety) |
| Current | Research compound |
References
- Frohman LA, et al. "Sermorelin: from basic science to clinical medicine." Horm Res. 1996.
- Walker RF, et al. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clin Interv Aging. 2006.
- Merriam GR, et al. "Growth hormone-releasing hormone and growth hormone secretagogues." Endocrinol Metab Clin North Am. 2007.